08-Aug-2008 - Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN

Cipher Pharmaceuticals Inc. announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions.

CIP-ISOTRETINOIN is a patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. The product received approvable letters from the U.S. Food and Drug Administration ("FDA") in May 2006 and April 2007 in which the FDA requested that Cipher provide additional clinical safety data. Cipher and its advisors are currently in discussions with the FDA's Division of Dermatology and Dental Products regarding the appropriate design of a safety study.

Under the terms of the agreement with RPI, Cipher received an initial upfront milestone payment of US$1 million. The agreement includes additional pre- and post-commercialization milestone payments of up to US$23 million, contingent upon the achievement of certain milestone targets. Once the product is successfully commercialized, Cipher will also receive a royalty in the mid-teens on net sales. In addition, RPI will reimburse Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally. Cipher is responsible for all product development activities, including management of the clinical studies required by the FDA to secure NDA approval. Cipher is also responsible for product supply and manufacturing, which would be fulfilled by its partner, Galephar Pharmaceutical Research. After product-related expenses are deducted, approximately 50% of all milestone and royalty payments received by Cipher under the agreement will be paid to Galephar.

Facts, background information, dossiers
  • FDA
  • Ranbaxy
  • milestone payments
More about Cipher Pharmaceuticals
  • News

    Cipher Pharmaceuticals acquires INNOCUTIS Holdings

    Onxeo S.A. announced Cipher Pharmaceuticals' acquisition of INNOCUTIS Holdings LLC, the licensee of Sitavig® in the USA. As a major step in the growth strategy of Cipher Pharmaceuticals, this acquisition provides Cipher with a commercial infrastructure and a talented sales team for the USA. ... more

    Cipher achieves major milestone with FDA approval for CIP-TRAMADOL ER

    Cipher Pharmaceuticals Inc. announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. "This represents our second FDA approval - a major achieveme ... more

    Cipher appoints Dr. William Claypool to Board of Directors

    Cipher Pharmaceuticals Inc. (announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors. Since October 2008, Dr. Claypool has been a Senior Partner at Pennmark Associates, LLC, a pharmaceutical development consulting firm. Prior to that, Dr. Claypool served as ... more

  • Companies

    Cipher Pharmaceuticals Inc.

    Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advanc ... more

More about Ranbaxy
  • News

    Sun Pharma announces closure of merger deal with Ranbaxy

    Sun Pharmaceutical Industries Ltd. begins the integration of Ranbaxy’s business following the successful closure of its merger.  The integration, planned by Sun Pharma over many months, will focus on supporting strong growth. The merger has fortified Sun Pharma’s position as the world’s fif ... more

    Ranbaxy to Bring in Daiichi Sankyo as Majority Partner

    Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Limited announced that a binding Share Purchase and Share Subscription Agreement (the "SPSSA") was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the largest and controlling shareholders of Ranbaxy (the "Sellers"). ... more

    Gilead Announces Generic Viriad Licensing Agreements with Eight India-Based Companies

    Gilead Sciences, Inc. announced that the company has signed eight new non-exclusive license agreements with generic companies in India. These licensing agreements grant to Alkem Laboratories Ltd., Aurobindo Pharma Ltd., FDC Ltd., J.B. Chemicals & Pharmaceuticals Ltd., Matrix Laboratories Lt ... more

  • Companies

    Ranbaxy Laboratories Ltd.

    Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ... more